Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Cost of goods sold was $239 million. R&D and SG&A expenses totaled $1.412 billion and $792 million, respectively. Notably, Regeneron’s R&D expenses grew 20% year-over-year.

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

San Francisco-based 23andMe filed for Chapter 11 bankruptcy protection in the Eastern Missouri federal court district in ...

Regeneron remains committed to supporting patient access to medications and believes that patients should be able to access whatever therapy their physician prescribes for them. In the past decade, ...